UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000010213
Receipt number R000011436
Scientific Title Effect of coadministration of angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB) on variability of home blood pressure in hypertensive outpatients
Date of disclosure of the study information 2013/04/01
Last modified on 2020/09/15 16:20:08

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of coadministration of angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB) on variability of home blood pressure in hypertensive outpatients

Acronym

Effect of ARB/CCB combination on home blood pressure variability

Scientific Title

Effect of coadministration of angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB) on variability of home blood pressure in hypertensive outpatients

Scientific Title:Acronym

Effect of ARB/CCB combination on home blood pressure variability

Region

Japan


Condition

Condition

Hypertension

Classification by specialty

Medicine in general Cardiology Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the effect of ARB/CCB combination on variability of home blood pressure in outpatients with hypertension resistive to single administration of ARB or CCB

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change of home blood pressure variability

Key secondary outcomes

1) Change of blood pressure at clinic and home
2) Change of pulse rate at clinic and home
3) Change of cardiac function (double product: pulse rate x systolic blood pressure)
4) Change of renal function (eGFR: estimated glomerular filtration rate)
5) Change of albuminuria
6) Incidence and degree of detrimental events


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Change from olmesartan medoxomil 20mg/day or azelnidipine 16mg/day to coadministration of olmesartan medoxomil 20mg and azelnidipine 16mg per day for a period of 16 weeks

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Hypertensive outpatients whose blood pressures show more than 135/85mmHg for the latest period of five consecutive days despite the administration of 16mg/day azelnidipine or 20mg/day olmesartan medoxomil for a period of more than four weeks
2) Patients who are able to measure home blood pressure on their own upper arms and to write the values down in the recording notebook
3) Patients with the informed consent to this study

Key exclusion criteria

1) Patients with the past history of hypersensitivity to test drugs, other ARBs or dihydropyridine CCBs
2) Female in current or expected pregnancy
3) Patients with the past history of cerebro-cardiovascular diseases within six months
4) Patients whose blood pressures show more than 180/110mmHg
5) Patients receiving the dialysis therapy or with severe renal dysfunction (eGFR<30ml/min/1.73m2)
6) Patients with severe hepatic dysfunction (showing more than 100 IU/L of AST or ALT)
7) Patients receiving treatment for a malignant neoplasm
8) Patients taking a contraindication drug for coadministration of test drugs
9) Patients judged as unsuitable for participating in this study by the attending physician

Target sample size

300


Research contact person

Name of lead principal investigator

1st name Naoki
Middle name
Last name Kashihara

Organization

Kawasaki Medical School

Division name

Department of Nephrology and Hypertension

Zip code

7010192

Address

577 Matsushima, Kurashiki, Okayama 701-0192

TEL

086-462-1111

Email

kashinao@med.kawasaki-m.ac.jp


Public contact

Name of contact person

1st name Hajime
Middle name
Last name Nagasu

Organization

Kawasaki Medical School

Division name

Department of Nephrology and Hypertension

Zip code

7010192

Address

577 Matsushima, Kurashiki, Okayama 701-0192

TEL

086-462-1111

Homepage URL


Email

hajimenagasu@kms-ndh.com


Sponsor or person

Institute

Department of Nephrology and Hypertension, Kawasaki Medical School

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kawasaki Medical School

Address

577 Matsushima, Kurashiki, Okayama 701-0192

Tel

086-462-1111

Email

kmsrec@med.kawasaki-m.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 04 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2013 Year 03 Month 11 Day

Date of IRB


Anticipated trial start date

2013 Year 04 Month 01 Day

Last follow-up date

2014 Year 10 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 03 Month 12 Day

Last modified on

2020 Year 09 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011436


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name